Glenn Bosch — Responds to a question about withdrawal symptoms and clarifies the discussion is about kratom itself.
Glenn Bosch — Is asked to clarify his statement about withdrawal symptoms.
Glenn Bosch — Is addressed with a question from Representative Porter.
Glenn Bosch — Is told the autopsy report was forwarded to him.
Cynthia Schreiber-Beck — Representative Heinert was referenced in connection with his prior explanation of the hearing process: legislators in the room would testify first, followed by individuals online, with comments kept to about five to seven minutes each.
Cynthia Schreiber-Beck — The speaker thanks Representative Scrow after finishing the comment.
Cynthia Schreiber-Beck — Representative Murphy addresses Representative Scrow and says the individual should probably continue using kratom as they have.
HB1101 — The speaker discusses House Bill 1101 as a 2025 bill introduced to place kratom in Schedule I under North Dakota’s controlled substances schedule. They note that the memorandum omitted HB 1101 despite extensive testimony on kratom, explain that the bill drew significant attention in House Judiciary, and describe its legislative fate: it received a 10-3 do-not-pass recommendation and then failed on the House floor by a 15-77 vote.
HB1101 — House Bill 1101 is discussed as a prior bill from last session that drew extensive public comment, written submissions, and testimony. It is identified as the measure that would have placed kratom on Schedule I, and speakers note that many people opposed it, including testimony about its impact on pain relief.
HB1566 — House Bill 1566 is discussed as a prior kratom-related bill that was not mentioned in the memorandum. The speaker explains that it was heard by the House Human Services Committee and was originally introduced to regulate kratom with restrictions and penalties. The bill was later amended to allow regulation by the Commissioner of Agriculture and a study, and then further amended in the Senate into a study-only approach. It is also referenced again as a prior bill suggesting regulation through the Agriculture Commissioner.
SuAnn Olson — SuAnn Olson of District 8 introduced herself and said she mainly wanted to echo Representative Klaman, then continued by sharing testimony about chronic pain and a family member’s experience with reflex sympathetic dystrophy.
Brandy Pyle — Representative Olson is referenced throughout a continuous discussion on kratom regulation, including her earlier comments, concerns about natural versus synthetic kratom, and later points about the potential consequences of disallowing use and the strain it could place on resources. The mentions collectively reflect an ongoing exchange responding to and building on her remarks.
Kristin Roers — Senator Roers is called on by the chair and begins speaking, discussing conversations with medical and public health stakeholders.
David Hogue — Referenced as the person being responded to earlier in the discussion about regulation versus a full ban.
Eric Murphy — Introduced as the next speaker after the prior remarks.
Eric Murphy — Speaker continues addressing the committee and references the earlier discussion.
Eric Murphy — The speaker addresses Representative Murphy multiple times in a continuous exchange about substance-related concerns. The discussion includes thanks to Murphy after raising overdose and naloxone issues, further references to Murphy in the same dialogue, and a later response to Murphy’s comment about overconsumption that compares kratom-related concerns with other legal substances.
Eric Murphy — Representative Murphy discusses enforcement of the kratom executive order, explaining that he spent Wednesday on the phone with law enforcement and BCI to understand how the order would be enforced. He says police characterized the issue as an infraction and that seizure of product was discussed with the governor’s office. Murphy reports that GFPD said stores would be given 72 hours to remove kratom and that it would not be seized from individuals at home. He adds that nearby retailers quickly removed kratom and shipped it to states where it is legal, and he praises the retail community for trying to comply while looking to lawmakers for guidance.
Bernie Satrom — Representative Satrom was referenced as being concerned about increasing access to Suboxone.
Dr. Hardy — The speaker says they have had long discussions with Dr. Hardy about how to address the issue, and adds that Dr. Hardy already has a list of substances that would need to be tightly limited.
Claire Cory — The speaker calls on Senator Cory next; likely a transcription error for Senator Claire Cory.
Todd Beard — Senator Beard is called on to speak, his comments are referenced in the broader discussion about regulation and adulterated products, the chair thanks him for his remarks, and a later speaker echoes his concerns about being proactive and preventing the industry from growing.
local physician — A local physician reportedly observed a rapidly rising spike of adolescents with severe withdrawal needing medical and inpatient treatment.
Dick Dever — Called on during roll call and marked present.
Pat Heinert — Representative Pat Heinert was called on during roll call and marked present, then introduced as beginning comments in his role as co-chair of the committee.
Todd Porter — Called on during roll call and marked present.
Todd Porter — Representative Porter raises a series of related questions about a reported mitragynine level, asking whether it could occur naturally or indicate synthetic derivation, how the number was calculated, and what guardrails might be needed to prevent dangerous compounding or similar outcomes. The speaker responds directly to Porter’s questions and later thanks him for his input, keeping the exchange centered on the same issue.
Robin Weisz — Called on during roll call and noted as online.
Glenn Bosch — Recognized as sitting with the group from Legislative Management.
Michelle Axtman — Senator Michelle Axtman is called during roll call and marked present, then is briefly addressed again as the meeting proceeds, including a later acknowledgment with a likely transcription error in her title/name.
Michelle Axtman — The speaker appears to address Senator Axtman.